Related Experiment Videos
Oral anticoagulation after myocardial infarction
1Department of Cardiology, Ullevål University Hospital, NO-0407 Oslo, Norway. herald.arnesen@ulleval.no
Thrombosis Research
|May 22, 2003
Summary
Oral anticoagulants (OAC) are superior to aspirin for long-term secondary prevention after myocardial infarction (MI). Careful monitoring is essential to balance efficacy and bleeding risk, with a combined OAC and aspirin regimen recommended.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atherothrombosis plays a key role in myocardial infarction (MI).
- Thrombin generation is a critical factor in MI pathophysiology, providing a rationale for anticoagulant therapy.
Purpose of the Study:
- To review the role of oral anticoagulants (OAC) in long-term secondary prophylaxis after myocardial infarction (MI).
- To compare OAC with aspirin, alone or in combination, based on recent randomized controlled trials (RCTs).
Main Methods:
- Review of recently published large randomized controlled trials (RCTs).
- Analysis of pathophysiological mechanisms of atherothrombosis in MI.
- Evaluation of clinical endpoints and bleeding complications associated with OAC therapy.
Main Results:
- Recent RCTs demonstrate the superiority of OAC over aspirin in reducing long-term clinical endpoints after MI.
- Optimal OAC effect requires understanding the narrow therapeutic window and ensuring patient compliance and strict treatment control.
- Specific INR thresholds for effective OAC prophylaxis, alone or with aspirin, are presented.
Conclusions:
- OAC therapy is more effective than aspirin for secondary prevention post-MI.
- Effective OAC use necessitates careful management of the therapeutic window to minimize bleeding risks.
- A combination of OAC (target INR 2.0-2.5) and low-dose aspirin (75 mg/day) is recommended.